Abstract

The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)’ are now available for access.

The present assessment addressed the research question whether the lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH) was more effective and/or safer than its comparators. The technology has been identified as the GreenLight XPS for which the manufacturer, Boston Scientific, claims advantages in terms of shorter hospital stay (because the procedure can be done as a day-case procedure); shorter duration of catheterisation; quicker return to normal activity following treatment; reduction in pain leading to improved quality of life; can be used for patients taking anticoagulants and those with larger prostates; reduction in hospital readmissions; reduced risk of capsular perforation, bleeding and TURP syndrome.